Global Human Microbiome-based Drugs Market

1. Global Human Microbiome-based Drugs Market

2. Summary The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly $9.9 billion by 2024. Study Goals and Objectives The objective of this study is to review the development of human microbiome-based drugs and diagnostics and assess their market potential for the U.S., Europe, Japan, China and rest of world geographies. We are particularly interested in characterizing the market for microbiome-based drugs for various diseases that are linked with the dysregulation in human microbiome. A focus of this report is to describe the microbial associations of various diseases, present a comprehensive profile of the microbiome-based drugs in the clinical development and finally provide the projections on the market size of microbiome-based drugs in various disease areas for the time period of 2018 to 2024.

4. Reasons for Doing This Study The human body is a home to over 100 trillion microbes and over 2 million microbial genes. Microbiome is a term that represents all of the microbial genes. So, the human microbiome is, in a sense, our second genome. Microbes residing inside and on the human bodies play a significant role in the body’s physiological functions—some beneficial and others harmful. Our knowledge and understanding of the role that microbes play in various diseases has grown exponentially since the completion of Human Microbiome Project in 2012. This field has seen a tremendous explosion in research and development activities in microbiome-based drugs and diagnostics. The field has also attracted substantial public and private sector investments. Collectively, these developments have created a new sector—human microbiome-based drugs and diagnostics.

5. Intended Audience We have compiled a study of microbiome-based drugs and diagnostics that will be important in key end-user segments. We analyze the microbiome-based drug market by indication (e.g., cancer, gastrointestinal diseases, metabolic disorders etc.), by type of product (e.g., live bacteria, engineered bacteria, bacterial mixtures etc.), and by region (i.e., the U.S. and the rest of the world, which includes Europe, China, Japan and other countries). We examine the microbiome’s scientific basis in various diseases, profile the microbiome products under development, and review intellectual property, corporate alliances and investments. We provide a holistic review of market potential and product sales forecasts by disease segment, by product and by region for the time period of 2017 to 2024.

6. Scope of Report The scope of the study includes the major microbiome-based drugs and diagnostics that are likely to be commercialized within the next eight years. Each product within each market is analyzed to determine its market status, market potential during the time period of 2018 to 2024. Microbiome intellectual property, investments and collaborations are discussed. Influencing factors, industry structure, challenges facing the industry and patent status are discussed. Research examines companies in the industry, corporate alliances and assay consumption by indication. We profile 25+ companies participating in this rapidly developing and evolving sector.

7. Information Sources Both primary and secondary information sources were used in preparing this study. Research interviewed life science companies and research institutions to obtain data for this study. Included were diagnostics, drug firms and leading research institutions. In addition, we compiled data from secondary sources, including industry, trade and government organizations.

8. Methodology Research presents an analysis of each of the key market segments that will be commercially important during the 2017–2024 period: microbiome-based drugs for gastrointestinal disorders (ulcerative colitis, Crohn’s disease, Clostridium difficle infection, lactose intolerance, celiac disease, hepatic encephalopathy and non-alcoholic steatohepatitis), cancer, bacterial infections (recurrent bacterial vaginosis and urinary tract infection, dental caries), orphan diseases (urea cycle disorders, phenylketonuria) and metabolic diseases (type 2 diabetes, obesity). We also conducted an analysis of microbiome-based diagnostics in various areas of disease.

9. Full Reports Global Human Microbiome-based Drugs Market Contact us atBharat Book Bureau Tel: +91 22 27810772 / 27810773 Email: poonam@bharatbook.com Our Blog: https://www.bharatbook.com/blog/ Twitter: https://twitter.com/researchbook Facebook: https://www.facebook.com/BharatBook3B LinkedIn: http://www.linkedin.com/company/bharat-book-bureau

10. THANK YOU